Neuropsychiatric systemic lupus erythematosus

Systemic Lupus Erythematosus (SLE)Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-specific Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the systemic lupus erythematosus (SLE) space target B-cell activating factor, glucocorticoid receptor, corticotropin releasing factor, and corticotropin releasing hormone.
  • The majority of industry-sponsored drugs in active clinical development for SLE are in Phase II, with only one drug in the NDA/BLA phase.
  • GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for SLE, followed by AstraZeneca.

Feinstein Institutes Receives $15 Million NIH Grant to Study Brain Dysfunction in Lupus

Retrieved on: 
Monday, July 20, 2020

The Feinstein Institutes for Medical Research has been awarded a $15 million grant to study brain dysfunction tied to lupus by the National Institutes of Health.

Key Points: 
  • The Feinstein Institutes for Medical Research has been awarded a $15 million grant to study brain dysfunction tied to lupus by the National Institutes of Health.
  • For up to 90 percent of those with lupus, their disease may impact their cognition, leading to the diagnosis of neuropsychiatric lupus (NPSLE).
  • With the NIHs support, we will study if common medications could protect against these negative effects of lupus.
  • As an internationally recognized leader in the field of lupus, Dr. Diamond has been supported by the NIH for many years, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes.

Global Systemic Lupus Erythematosus Report, 10-Year Forecasts, 7MM Coverage and Detailed Pipeline Product Profiles

Retrieved on: 
Wednesday, April 1, 2020

According to the American College of Rheumatology Systemic lupus erythematosus, referred to as SLE or lupus, is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs.

Key Points: 
  • According to the American College of Rheumatology Systemic lupus erythematosus, referred to as SLE or lupus, is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs.
  • The Systemic Lupus Erythematosus epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries.
  • Among 7MM, the United States has the highest prevalent population of Systemic Lupus Erythematosus with about 259,474 cases in 2017.
  • The report covers a descriptive overview of the Systemic Lupus Erythematosus, explaining its causes, risk factors, pathophysiology, and diagnosis.